The objective of this study is to demonstrate bioequivalence of 4 mg tablet of formulation D and formulation E(1).
- Healthy male or female Chinese or Japanese subjects
- Evidence or history of clinically significant findings at screening
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Pfizer Clinical Trials Contact Center
call now email
Contact a representative by phone, email, or visiting the study website. Please see the references below: